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Abstract
Drug combinations are increasingly important in disease treat-
ments, for combating drug resistance, and for elucidating funda-
mental relationships in cell physiology. When drugs are combined,
their individual effects on cells may be amplified or weakened.
Such drug interactions are crucial for treatment efficacy, but their
underlying mechanisms remain largely unknown. To uncover the
causes of drug interactions, we developed a systematic approach
based on precise quantification of the individual and joint effects
of antibiotics on growth of genome-wide Escherichia coli gene dele-
tion strains. We found that drug interactions between antibiotics
representing the main modes of action are highly robust to genetic
perturbation. This robustness is encapsulated in a general principle
of bacterial growth, which enables the quantitative prediction of
mutant growth rates under drug combinations. Rare violations of
this principle exposed recurring cellular functions controlling drug
interactions. In particular, we found that polysaccharide and ATP
synthesis control multiple drug interactions with previously unex-
plained mechanisms, and small molecule adjuvants targeting these
functions synthetically reshape drug interactions in predictable
ways. These results provide a new conceptual framework for the
design of multidrug combinations and suggest that there are
universal mechanisms at the heart of most drug interactions.
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Introduction
Drugs play a crucial role in elucidating fundamental relationships in
cell physiology (Falconer et al, 2011). When drugs are combined,
interactions like synergism and antagonism can occur (Loewe,
1928; Keith et al, 2005) (Fig 1A); such drug interactions are often
critical for the success of multidrug treatments (Pillai et al, 2005)
and can slow or accelerate antibiotic resistance evolution (Chait
et al, 2007; Hegreness et al, 2008). A case in point is the synergistic
combination of trimethoprim and sulfa drugs which has been
applied successfully for decades (Pillai et al, 2005) even though the
mechanism of synergism has long remained elusive (Nichols et al,
2011). Synergism and antagonism occur frequently between antimi-
crobials and are largely determined by the primary cellular target of
the drugs that are combined (Yeh et al, 2006; Ocampo et al, 2014).
However, synergistic drug interactions are rarely explained by the
genetic interactions between the corresponding drug target genes
(Cokol et al, 2011). To design combinations exploiting the full
potential of existing drugs, a deeper understanding of the underlying
mechanisms of drug interactions is urgently needed. Due to the vast
number of possible drug combinations, general principles that are
valid across diverse drug pairs could greatly facilitate the identifica-
tion of drug interaction mechanisms. Recent work in this direction
revealed scaling laws describing the effects of resistance mutations
on drug interactions (Chait et al, 2007; Wood et al, 2014); further,
the effects of three or more drugs appear largely predictable from
the two-drug effects (Wood et al, 2012). However, the underlying
mechanisms of most two-drug interactions remain unknown.
Drug interactions could be caused by physicochemical effects, for
example when one drug simply enhances the permeability of the cell
envelope for another (Jawetz & Gunnison, 1953); alternatively, they
may have more complex causes, specifically if one drug triggers a regu-
latory response, which affects the action of another. While many genes
affect the cell’s sensitivity to individual drugs (Hillenmeyer et al, 2008;
Nichols et al, 2011) and recent work suggested that certain drug resis-
tance mutations may affect drug interactions (Munck et al, 2014; Wood
et al, 2014; Rodriguez de Evgrafov et al, 2015), it is unclear to what
extent genetic perturbations can alter drug interactions. Likewise, the
cellular functions that control these interactions are largely unknown.
To pinpoint their underlying causes, we developed a systematic
approach for identifying genes that reshape drug interactions: using
precise growth rate measurements of a genome-wide set of E. coli gene
deletion mutants (Baba et al, 2006), we show that drug interactions are
robust to most, but not all, genetic changes. We present a general prin-
ciple encapsulating this robustness, which enables the quantitative
prediction of mutant growth under drug combinations. Rare mutants
violating this principle expose cellular functions governing each drug
interaction. We establish that diverse drug interactions are recurrently
controlled by central cellular functions, in particular polysaccharide
synthesis and ATP synthesis.
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Results and Discussion
We began by quantifying the growth rates of ~4,000 nonessential
E. coli gene deletion mutants (Baba et al, 2006) under six different
antibiotic pairs and their constituent individual drugs (Materials and
Methods). We selected antibiotics with diverse modes of action
(Table 1) and drug pairs covering all interaction types (Fig 1A and
B). Drug concentrations were adjusted to inhibit wild-type growth
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Figure 1. Systematically identifying genes that affect drug interactions.
A Schematic: lines of equal growth (isoboles) in two-dimensional concentration space of drugs A and B; isobole shape determines drug interaction (Loewe, 1928).
Synergistic drug pairs have stronger than additive, antagonistic ones weaker than additive effect on growth. In suppressive interactions, the combination effect is
weaker than that of one of the drugs alone.
B Interaction network for six antibiotics: synergism is red; antagonism, green; suppression, blue; stars show drug combinations investigated here.
C Schematic illustrating approach, see the text for details.
D Wild-type E. coli (WT) growth curves without drug (black), under chloramphenicol (blue), nitrofurantoin (yellow), and chloramphenicol–nitrofurantoin combination
(green); magenta lines are exponential fits (Materials and Methods).
E As (D) for the rssB mutant which has a lower growth rate but unchanged drug interaction.
F Scatterplot: growth rates of ~4,000 E. coli gene deletion mutants under chloramphenicol and nitrofurantoin alone and under the combination (color scale).
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under individual drugs by ~30%; the same concentrations were
used when drugs were combined, leading to different levels of
growth inhibition (Materials and Methods). In total, we measured
over 50,000 growth curves (optical density increase over time) using
a dedicated robotic system (Fig 1C–F; Materials and Methods).
These growth rate measurements were highly reproducible (Supple-
mentary Fig S1), and consistent with established changes in mutant
sensitivity to individual antibiotics (Tamae et al, 2008; Liu et al,
2010; Nichols et al, 2011): for example, DNA repair mutants were
sensitive to ciprofloxacin. Drugs with related mode of action had
similar effects on growth of genome-wide mutants (e.g., Pearson
correlation q = 0.68 for chloramphenicol and tetracycline), and the
effects of drug combinations were usually most similar to those of
the constituent drugs (Supplementary Fig S2; Materials and Meth-
ods). These observations confirmed our expectation that perturba-
tions of cell physiology caused by drug combinations are mostly an
overlay of effects caused by the constituent drugs.
We next identified a general principle characterizing drug inter-
actions in mutants. We hypothesized that the shape of the two-drug
growth response surface g(a,b), which defines the interaction
(Fig 1A), does not change qualitatively in most mutants (here, g
denotes growth rate and a, b the drug concentrations). To test this
hypothesis, we measured 108 mutant response surfaces in two-
dimensional drug concentration matrices covering different drug
pairs; this selection included mutants with strongly altered sensitiv-
ity to the individual drugs (Materials and Methods). We found that
the vast majority of mutant response surfaces gmut(a,b) were well
approximated by a linearly rescaled wild-type surface: gmut(a,b) =
cgWT(aa,bb) with scaling factors for maximum growth rate c and for
drug concentrations a, b (Fig 2A and B; Supplementary Figs S3 and
S4). The sensitivity to one or both of the drugs often changed
considerably, yet the response surface shape was generally
preserved (Fig 2A); these observations held for all drug pairs and
for mutants affecting diverse cellular functions (Fig 2B; Supplemen-
tary Fig S4), suggesting that most genetic perturbations do not affect
drug interactions.
To test whether this conservation of drug interactions holds
generally, we devised a strategy for predicting genome-wide mutant
growth responses to drug combinations. For all ~4,000 mutants, we
calculated the expected response to the drug combination by first
rescaling the wild-type response surface according to the individual
drug responses measured at fixed concentrations. At the rescaled
drug concentrations, we then used the interaction coefficient of the
wild-type, which quantifies the response to the drug combination
relative to the Bliss additive expectation (Yeh et al, 2006), to calcu-
late each mutant’s expected growth rate under the drug combination
(Fig 2C; Materials and Methods). The central assumption of this
procedure is that the drug interaction is universally invariant, that is
it is the same in mutants as in the wild-type upon rescaling of the
drug concentrations. For all drug pairs and the vast majority of
mutants, the growth rates measured at fixed concentration of the
drug combination (Fig 1C–F) faithfully followed this prediction
(Fig 2D; Supplementary Fig S5). These observations thus revealed a
general principle of bacterial growth under drug combinations,
which encapsulates the high robustness of drug interactions to
genetic perturbations and enables the quantitative prediction of
mutant growth rates under drug combinations.
The identification of this general principle empowered us to
pinpoint ‘outlier’ mutants with unexpected growth response to
drug combinations. These outliers are of key interest as they could
have altered drug interaction; together with functional information
on the mutated gene, they can thus point at the underlying drug
interaction mechanism. Clear outliers for which the observed
growth rate under the drug combination (Fig 1F) deviated signifi-
cantly from the expected growth rate were rare (typically < 1% of
mutants; Fig 2D; Supplementary Fig S5), facilitating this investiga-
tion. We measured the response surface of the strongest outliers
for each drug combination in fine resolution 12 × 8 concentration
matrices (Materials and Methods). For each drug pair, we thus
identified several mutants with clearly reshaped drug interaction
(Fig 3, Supplementary Fig S6). Drug interactions were often weak-
ened or removed in these mutants; they were also amplified in
certain mutants and, in some cases, entirely new ‘synthetic’ drug
interactions appeared (Fig 3C). In a thiamin synthesis hypomorph,
chloramphenicol–trimethoprim even became reciprocally suppres-
sive; that is, addition of chloramphenicol on top of trimethoprim
increased growth and vice versa (Supplementary Fig S7). We
further observed clear biases in interaction changes: chlorampheni-
col–nitrofurantoin suppression was weakened or entirely removed
in most mutants affecting this interaction (Fig 3A); in contrast,
chloramphenicol–trimethoprim antagonism was often amplified to
suppression (Fig 3B and C; Supplementary Fig S6L–Q), while other
drug combinations showed more balanced interaction changes in
both directions (Supplementary Fig S5). These data show that
different drug combinations have varying potential for changing
their drug interaction type, even if the wild-type interaction is
similar. Interestingly, for the additive chloramphenicol–tetracycline
combination, none of the outlier mutants showed any change in
drug interaction: while the sensitivity to the constituent drugs
often changed, additivity was generally preserved (Supplementary
Fig S3). This observation is consistent with previous results that
this interaction changed little in strains that had evolved resistance
to chloramphenicol–tetracycline (Munck et al, 2014). Thus, the
chloramphenicol–tetracycline drug interaction appears robust to
genetic perturbations. Together, these data show that most drug
interactions can be removed, amplified, and even qualitatively
Table 1. Antibiotics used in this study.
Abbreviation Drug
Mode of action
(known target) Concentration
CHL Chloramphenicol Protein synthesis
(50S ribosome
subunit)
1 µg/ml
CPR Ciprofloxacin DNA replication
(gyrase)
4 ng/ml
MEC Mecillinam Cell wall
(Penicillin
Binding Protein)
38 ng/ml
NIT Nitrofurantoin Multiple
mechanisms
2 µg/ml
TET Tetracycline Protein synthesis
(30S ribosome
subunit)
150 ng/ml
TMP Trimethoprim Folic acid
synthesis (DHFR)
80 ng/ml
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changed to a different interaction type by rare genetic perturba-
tions, while other interactions are robust.
We next identified cellular functions controlling drug interac-
tions; among these, the synthesis of secreted polysaccharides (cap-
sular and lipopolysaccharides, LPS) and ATP synthesis stood out in
that they affected virtually all drug interactions. Firstly, manual
inspection of the functional annotation of the outlier mutants (Keseler
et al, 2005) for each drug pair, and systematic gene ontology enrich-
ment analysis congruently exposed specific functions controlling the
respective interaction (Fig 3D, Supplementary Table S1, Materials
and Methods): for example, perturbing tRNA processing consistently
removed chloramphenicol–nitrofurantoin suppression (Fig 3A
and C; Supplementary Fig S6X and Y); similarly, ribosome produc-
tion and assembly altered ciprofloxacin–tetracycline suppression
(dksA, rsgA, ksgA in Supplementary Fig S5C; Supplementary Table
S1), confirming previous results (Bollenbach et al, 2009). Secondly,
we noticed that certain functions recurrently control multiple drug
interactions. Besides polysaccharide and ATP synthesis (discussed
below), chaperone deletions (ppiD, dnaK) consistently caused
amplified or synthetic suppression for distinct drug pairs
and perturbing amino acid synthesis (metL) amplified chloramphe-
nicol–nitrofurantoin suppression but removed trimethoprim–
chloramphenicol antagonism (Fig 3C, Supplementary Fig S6). Thus,
multiple drug interactions are controlled by few recurring cellular
functions.
Polysaccharide synthesis affects the majority of drug interactions
(Fig 3C and D; Supplementary Fig S6): perturbing this function
removed chloramphenicol–nitrofurantoin suppression and trimetho-
prim–mecillinam synergy (gmhB, rcsD in Fig 3C; lpcA in Supple-
mentary Fig S6); in contrast, it led to synthetic suppression between
trimethoprim and chloramphenicol (lpxM in Fig 3C; Supplementary
Fig S6M and N). Polysaccharide synthesis mutants have modified
outer membrane composition, which affects the uptake of molecules
dependent on their chemical properties (Nikaido & Vaara, 1985).
Hence, a plausible cause of these drug interactions is that bacteria
regulate polysaccharide synthesis in response to certain antibiotics,
which then affects the uptake of other drugs. Consistent with this
mechanism, antibiotics are known to affect polysaccharide synthesis
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Figure 2. Drug interactions do not change for most gene deletions, enabling the quantitative prediction of mutant growth rates under drug combinations.
A Growth of WT (top) and zwf mutant (bottom) across two-dimensional chloramphenicol–nitrofurantoin concentration space; IC50 lines are magenta (WT) and cyan
(zwf).
B Top row: IC50 lines of WT and mutants for antibiotic combinations with different drug interactions: chloramphenicol–nitrofurantoin (suppressive), chloramphenicol–
trimethoprim (antagonistic), chloramphenicol–tetracycline (additive), trimethoprim–mecillinam (synergistic). Bottom row: IC50 lines upon concentration rescaling (see
text). While sensitivity to individual drugs changes in mutants, the drug interaction does not (see also Supplementary Figs S3 and S4). Magenta lines show WT.
C Schematic: calculation of expected mutant growth rates under drug combinations assuming concentration rescaling as in (A, B) (Materials and Methods).
D Scatterplot: measured versus expected mutant growth rates under chloramphenicol–trimethoprim; identity line is in solid magenta; dashed magenta lines show 95%
confidence interval (Materials and Methods).
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(Rothfield & Pearlman-Kothencz, 1969) and LPS synthesis mutants
have increased sensitivity to chloramphenicol (Fig 3C; Supplemen-
tary Fig S6V); thus, stimulation of LPS synthesis by nitrofurantoin
could explain chloramphenicol–nitrofurantoin suppression. To
directly test this scenario, we removed outer membrane LPS using
ethylenediaminetetraacetic acid (EDTA) (Nikaido & Vaara, 1985).
Strikingly, LPS removal increased sensitivity to chloramphenicol,
abolished chloramphenicol–nitrofurantoin suppression, and
rendered this drug interaction purely additive (Fig 4A and B).
Together, these data support that regulated changes in cell envelope
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Figure 3. Drug interactions are controlled by a confined set of recurring cellular functions.
A Scatterplot: deviation from expectation of measured mutant growth rates under chloramphenicol–nitrofurantoin versus expected growth rate; dashed magenta lines
show 95% confidence interval (Materials and Methods); mutants above this region have amplified antagonism, mutants below weakened antagonism.
B As (A) for chloramphenicol–trimethoprim.
C Growth of mutants in two-dimensional concentration gradients of chloramphenicol–nitrofurantoin (top), chloramphenicol–trimethoprim (middle), and trimethoprim–
mecillinam (bottom). Outlier mutants have altered drug interactions in agreement with the results shown in (A, B). Drug interactions change in polysaccharide
synthesis (gmhB, lpxM, rcsD; green), ATP synthesis (atpF; blue), chaperoning (dnaK, ppiD; orange), and amino acid synthesis (metL; magenta) mutants; see also
Supplementary Fig S6.
D Clustergram showing gene ontology terms enriched among outliers for multiple drug pairs and corresponding P-values (Materials and Methods, Supplementary
Table S1).
ª 2015 The Authors Molecular Systems Biology 11: 807 | 2015
Guillaume Chevereau & Tobias Bollenbach Systematic discovery of drug interaction mechanisms Molecular Systems Biology
5
Published online: April 29, 2015 
composition, which affect drug uptake, are a recurring mechanism
underlying chloramphenicol–nitrofurantoin suppression and other
antibiotic interactions.
ATP synthesis also controls multiple drug interactions (Fig 3C
and D). Specifically, the ATP synthase mutant atpF was more sensi-
tive to trimethoprim and this sensitivity was reduced by chloram-
phenicol or mecillinam, leading to suppression (Fig 3C); a similar
effect occurred for ciprofloxacin–tetracycline (Supplementary Fig
S6S). A thiamin synthesis hypomorph, which also has perturbed
energy metabolism, behaved similarly (Supplementary Fig S7).
Further, ATP synthase expression increased two-fold in response to
trimethoprim (Supplementary Fig S8), suggesting that cells respond
homeostatically to ATP deficiency. To test independently whether
ATP synthesis affects drug interactions, we specifically blocked the
proton pore of the ATP synthase FO subunit using drugs (oligomy-
cin, venturicidin; Materials and Methods). Indeed, inhibiting ATP
synthase led to suppression between trimethoprim and chloramphe-
nicol (Fig 4C and D; Supplementary Fig S9), supporting that imbal-
ances in energy metabolism cause this synthetic drug interaction.
Together, these data suggest a mechanistic scenario in which
impaired ATP synthase function leads to decreased intracellular
ATP levels, which may become growth-limiting in the presence of
trimethoprim or ciprofloxacin; concurrent translation inhibition by
chloramphenicol would reduce global ATP turnover, replenish the
intracellular ATP pool (Schneider et al, 2002), and thus lead to
increased growth, which would explain the observed suppressive
interaction. No suppression would occur in the wild-type where
ATP is likely in excess and not growth-limiting. At a molecular
level, decreased ATP concentrations might limit growth by aggravat-
ing DNA repair and synthesis (Waldstein et al, 1974), which is
likely the growth-limiting process in the presence of drugs targeting
DNA synthesis; however, other ATP-dependent processes could also
contribute to suppression. Overall, our results show that perturba-
tions of central cellular functions, unrelated to the common anti-
biotic targets, can reshape diverse drug interactions.
We established a general principle of bacterial growth, which
enables the prediction of mutant growth rates under drug combina-
tions from their growth under the individual drugs alone (Fig 2,
Supplementary Fig S5). This principle may hold more generally and
should be tested for combinations of other challenges such as
osmotic, temperature, or pH stress in future work. While conceptu-
ally similar empirical laws are an integral part of physics, they are
still scarce in biology (Scott & Hwa, 2011). Even without under-
standing their molecular origins, such principles are powerful since
they enable the prediction of quantitative phenotypes. Here, such a
principle was crucial for systematically revealing antibiotic interac-
tion mechanisms.
The identification of cellular functions controlling drug interac-
tions offers new strategies for the rational design of multidrug
combinations. Specifically, we identified targets for potential adju-
vants, which could reshape antibiotic interactions: thiamin synthe-
sis inhibitors could render the chloramphenicol–trimethoprim
combination reciprocally suppressive (Supplementary Fig S7); such
reciprocal suppression may slow down resistance evolution but is
extremely scarce among natural antibiotic interactions (Chait et al,
2007). LPS synthesis inhibitors could remove chloramphenicol–
nitrofurantoin suppression (Fig 4A and B), thus preserving advanta-
ges of an untapped drug combination while increasing its potency.
Drugs inhibiting cellular functions that control antibiotic interac-
tions (LPS synthesis, ATP synthesis, and chaperoning; Fig 3C and
D) are in development (Moreau et al, 2008; Evans et al, 2010; Du
et al, 2011; Balemans et al, 2012). These inhibitors could reshape
drug interactions even if they have poor antimicrobial activity alone
since most mutants we identified have only mild growth defects.
Finally, our approach revealed that certain drug combinations are
robust to mutations (Supplementary Fig S3) or change primarily
toward weakened antagonism (Fig 3A). The origins of such robust-
ness and biases in drug interaction changes are unknown. Still, such
insights can be used to avoid loss of synergism due to mutations
occurring in treatments, which is a serious concern (Pena-Miller
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et al, 2013; Munck et al, 2014). It will be exciting to extend the
systematic approach presented here to drug interactions in other
systems including the most worrisome pathogenic microbes and
cancer.
Materials and Methods
Strains, media, and drugs
Deletion strains are from the Keio collection of 3,985 nonessential
gene deletions (Baba et al, 2006). Since the strains in this collection
have a kanamycin resistance marker, we introduced kanamycin
resistance on a low-copy-number plasmid (pUA66; Zaslaver et al,
2006) into the parent strain (BW25113, ‘WT’). All gene deletion
mutants with clear effects on drug interactions (pgpA, gmhB, metL,
ppiD, lpxM, atpF, rcsD, dnaK, atpC, rfaG, rfaP, rfaC, lpcA, rep, spr)
were verified by sequencing; the correct gene deletion was
confirmed in all cases. All experiments were performed in lysogeny
broth (LB) medium. Drugs were obtained from Sigma-Aldrich (cata-
logue numbers: ciprofloxacin, 17850; chloramphenicol, C0378;
mecillinam, 33447; nitrofurantoin, N7878; tetracycline, 268054;
trimethoprim, 92131). Drug stocks were prepared in water (cipro-
floxacin, mecillinam), ethanol (chloramphenicol, tetracycline,
trimethoprim) or dimethylformamide (nitrofurantoin), passed
through a 0.22-lm filter, and stored in the dark at 20°C. Drugs
were used at fixed concentrations that inhibit wild-type growth by
~30% (Table 1); growth remained exponential at the concentrations
used (Fig 1D and E). In drug combination experiments, the same
concentration as in the single drug experiments was used except for
mecillinam–trimethoprim for which no growth occurred at these
concentrations due to its synergistic interaction; therefore, the
concentration of both drugs was reduced in the combination experi-
ment (20 ng/ml for mecillinam and 50 ng/ml for trimethoprim).
The resulting growth inhibition of the wild-type was ~60% for
chloramphenicol–tetracycline, ~50% for chloramphenicol–trimetho-
prim, ~20% for ciprofloxacin–tetracycline, ~55% for mecillinam–
trimethoprim, ~35% for trimethoprim–tetracycline, and ~30% for
nitrofurantoin–chloramphenicol. Thiamin pyrophosphate (Sigma-
Aldrich catalogue number C8754) was dissolved in water and stored
in the dark at 20°C. Oligomycin A and venturicidin A (Szabo Scan-
dic catalogue numbers SACSC-201551A and SACSC-202380A) were
dissolved in ethanol and stored in the dark at 20°C.
Growth rate measurements
Each strain was incubated for ~20 h in one well of a 96-well plate
(nontreated transparent flat bottom, Nunc) containing 200 ll
medium. Cultures were inoculated using a replicator (V&P Scien-
tific) transferring ~0.2 ll from a (thawed) overnight culture kept at
80°C with 15% glycerol. Optical density (OD) at 600 nm was
measured every ~30 min in a plate reader (Tecan Infinite F500, 5
flashes, 10 ms settle time; filter: D600/20×; Chroma). The plates
were incubated in an automated incubator (Liconic Storex) kept at
30°C, > 95% humidity, and shaken at 720 rpm. In addition, directly
before each measurement, plates were shaken on a magnetic shaker
(Teleshake; Thermo Scientific) at 900 rpm for 20 s. A customized
liquid handling robot (Tecan Freedom Evo 150) was used to
automate these experiments and measure over 2,000 growth curves
per day. To achieve nearly identical growth conditions for all strains
in each condition, the growth curves of all ~4,000 deletion strains
were measured over two consecutive days using the same freshly
prepared drug solution. The growth rate in exponential phase was
quantified from the OD increase over time by a linear fit of log(OD)
in the range 0.022 < OD < 0.22 (magenta lines in Fig 1). Late
growth occurring after 1,000 min was discarded because in rare
cases, fast growing strains (likely resistant mutants) overtook the
population. For mecillinam, only early growth (happening before
450 min) was considered because many instances of late fast growth
occurred for this drug; this effect may be due to drug decay as mecil-
linam is relatively unstable (Baltzer, 1979). All growth rates were
normalized to the growth rate of the parent strain in the absence of
drug measured on the same day. These automated measurements
led to highly reproducible growth rates: replicate measurements of
the entire deletion collection under chloramphenicol on different
days showed a Pearson correlation of 0.94 (Supplementary Fig S1A);
replicates of growth rate measurements had a variation coefficient
(standard deviation over mean) of typically < 5%. Media evapora-
tion from plates and edge effects were virtually undetectable. Mutant
sensitivities to antibiotics determined from these data were consis-
tent with published data (Supplementary Fig S10).
Two-drug response surfaces
For each drug pair, response surfaces were measured for wild-type
and 18 gene deletion mutants, covering outlier mutants with strong
differences between observed and expected growth rate (Fig 3A and
B; Supplementary Fig S5) and additional mutants that showed clear
changes in sensitivity to at least one of the constituent drugs.
Response surfaces were measured using 12 × 8 or 24 × 24 two-
dimensional drug concentration matrices set up with a liquid hand-
ling robot across one (12 × 8) or six 96-well plates (24 × 24),
respectively. The concentration profile for each drug was set up
according to c ¼ cmax x3þax1þa ; where cmax was the highest concentra-
tion used, x was linearly spaced from 0 to 1 with 8, 12, or 24 steps
depending on the experiment, and a = 1/3. This concentration
profile was chosen to adequately sample the relevant part of the
two-drug response surface where growth rate changes significantly.
The points in two-dimensional concentration space where growth
was measured are shown by small gray dots in all Figures. For the
representation of two-dimensional response surfaces, we used the
optical density 12 h after inoculation instead of the growth rate
because this quantity was slightly more reproducible and yielded
smoother response surfaces; this representation does not affect any
of the conclusions on drug interaction changes (Supplementary Fig
S1B–D). Smooth surfaces and isoboles (contour lines) were calcu-
lated by linear interpolation (Matlab function interp2) of the experi-
mental data. The IC50 line is the isobole of 50% growth inhibition,
and in practice, we used the isobole of 90% growth inhibition as the
MIC (Minimal Inhibitory Concentration) line. We measured the
response surface of the wild-type and of all mutants that showed a
clear change in drug interaction (Fig 3C; Supplementary Fig S7) at
least in duplicate; replicate response surfaces measured on different
days were generally highly reproducible (Supplementary Fig S1B–D)
and, in particular, all drug interaction changes in mutants were
confirmed.
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Expected growth rate in drug combinations
We calculated the expected growth rate (Fig 2D; Supplementary Fig
S5) for each mutant strain i in the combination of drugs A and B at
concentration a and b, respectively, using the following procedure:
(i) The effective concentration aieff of drug A experienced by
mutant i was calculated from the response riðaÞ ¼ giðaÞ
gið0Þ of this
mutant to drug A at concentration a alone; here, gi(a) and
gi(0) denote the growth rate of mutant i in the presence and in
the absence of drug A, respectively. Specifically, this was done
by identifying the concentration in the WT dose–response
curve rWT(a), which corresponds to the same response; that is
we determined aieff such that r
WTðaieffÞ ¼ riðaÞ; analogously, we
calculated bieff. The scaling factors for the drug concentration
are then given by ai ¼ aieff=a and bi ¼ bieff=b and that for the
growth rate is given by ci = gi(0)/gWT(0). This procedure
exploits the observation that the dose–response curve ri (a) of
mutants is generally the same as the wild-type curve with a
linearly rescaled drug concentration.
(ii) The interaction coefficient IWT was calculated at position
ðaieff; bieffÞ in the two-drug space (Fig 2C). This interaction coeffi-
cient of the WT was defined as the measured response compared
to the Bliss additive expectation IWTða; bÞ ¼ rWTða;bÞrWTðaÞrWTðbÞ (Yeh
et al, 2006). The WT response surfaces for all drug pairs were
measured in a fine resolution 24 × 24 concentration matrix to
enable the precise determination of IWT.
(iii) The expected growth rate of mutant i in the combination of
both drugs at concentrations a, b was then giða;bÞ ¼
gið0Þ  riðaÞ  riðbÞ  IWTðaieff; bieffÞ; this equation formalizes the
assumption that the interaction coefficient is a universal
invariant and, for all mutants, is the same as in the WT at the
effective drug concentrations.
This procedure yielded accurate predictions of growth rate under
drug combinations (Fig 2D; Supplementary Fig S5). For mecillinam–
trimethoprim, we had to slightly adjust this procedure since the
concentrations used in the drug combination had to be reduced (see
‘Strains, media, and drugs’ above). We took this into account by
multiplying aieff and b
i
eff with a constant factor capturing the reduced
drug concentrations. Mutants that deviated from this expectation
were used to identify altered drug interactions (Fig 3, Supplemen-
tary Fig S5); some mutants deviated from this expectation for other
reasons, in most cases because they had extremely long lag phase.
To estimate the error of the expected growth rate, we added a 5%
normal distributed relative error (empirically determined, see
‘Growth rate measurements’ above), and an estimated absolute
error of 0.01 (capturing the limited reproducibility of extremely low
growth rates) to each growth rate measurement. The standard devi-
ation at each expected growth rate was then numerically calculated
from 10,000 randomly sampled growth rates g(a) and g(b) (from a
uniform distribution between 0 and 1) for each drug pair. The
dashed lines in Figs 2D and 3A and B, and Supplementary Fig S5
show two standard deviations (corresponding to a 95% confidence
interval) for both the expected (x-axis) and the measured growth
rate in the combination (y-axis). Due to differences in response
surface shape, the resultant error estimates depend strongly on the
drugs used. The density scatterplots in these and other Figures were
generated using the scatplot function available at http://www.math
works.com/matlabcentral/fileexchange/8577-scatplot.
Gene ontology enrichment analysis
To identify mutants whose growth rate in the drug combination
deviated strongly from the expectation (outliers in Fig 3A and B;
Supplementary Fig S5), we performed an orthogonal regression
using principal component analysis (Matlab function princomp) and
used the orthogonal distance to the regression line to quantify devia-
tions from the expectation. We performed gene ontology enrichment
analysis (Fig 3D; Supplementary Table S1) on the 30 outliers with
the strongest deviation from the expectation. We excluded outliers
for which both the expected and the observed growth rates were
below 0.15 because these extremely low growth rates are hard to
quantify reliably. The gene ontology database used in our analysis
was retrieved from geneontology.org (released 07/15/2014) and
the gene association file linking gene names to GO numbers
from ecocyc.org (GOC validation date: 06/26/2014) (Keseler et al,
2005). The P-values were obtained using a custom implementation
of Sherlock and Weng’s GO:Termfinder software (Tavazoie
et al, 1999) and Bonferroni corrected for the number of GO terms
tested.
Gene expression measurements
Transcriptional regulation of the atpI promoter was measured as a
proxy for ATP synthase expression in concentration gradients of
different antibiotics using a promoter–GFP reporter strain (Zaslaver
et al, 2006) and quantified as described (Bollenbach et al, 2009).
Supplementary information for this article is available online:
http://msb.embopress.org
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